Klaus A. Dugi - Concepedia

Author

Klaus A. Dugi

Also Known As

K A Dugi, K Dugi, K. A. Dugi, K. Dugi, K.A Dugi, K.A. Dugi, Klaus A Dugi, Klaus A. Dugi, Klaus Dugi, Santamarina-Fojo, Silvia

Publications

5.5K

Citations

H-Index

Concepts

All Affiliations

Boehringer Ingelheim (Germany)Heidelberg University National Heart Lung and Blood Institute National Institutes of Health Boehringer Ingelheim (Japan)

About

Klaus A. Dugi is an author at Boehringer Ingelheim (Germany) specializing in medicine, atherosclerosis, and diabetes.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	18	1.4K
2	Biochemistry	7	7	478
3	Health Sciences	6	6	347
4	Public Health	4	4	545
5	Natural Sciences	1	1	129

Klaus A. Dugi

Publications

Citations

H-Index

Page 1

	Year	Citations
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial Baptist Gallwitz, Julio Rosenstock, T. Rauch, The Lancet Non-pharmacological InterventionDiabetes ManagementHealth PolicyCardiovascular Disease2-Year Efficacy	2012	336
Effect of linagliptin monotherapy on glycaemic control and markers of <i>β</i> ‐cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial Stefano Del Prato, Anthony Barnett, Holger Huisman, Diabetes Obesity and Metabolism	2010	296
Safety and efficacy of linagliptin as add‐on therapy to metformin in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled study Marja‐Riitta Taskinen, Julio Rosenstock, Ilkka Tamminen, Diabetes Obesity and Metabolism	2010	292
Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24‐week randomized study<sup>1</sup> D. R. Owens, Ros Swallow, Klaus A. Dugi, Diabetic Medicine	2011	211
Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double‐blind, placebo‐controlled study Ramón Gomis, Rosa-Maria Espadero, Russell Jones, Diabetes Obesity and Metabolism	2011	176
Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase‐4 inhibitor in male type 2 diabetes patients Tim Heise, Eva U. Graefe-Mody, S. Hüttner, Diabetes Obesity and Metabolism	2009	174
Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease Maximilian von Eynatten, Philipp M. Lepper, D. Liu, Diabetologia Insulin ResistanceMetabolic SyndromeInsulin SignalingMetabolic DisorderBiochemistry	2007	171
Activation of Tubular Epithelial Cells in Diabetic Nephropathy Michael Morcos, Ahmed Sayed, Angelika Bierhaus, Diabetes	2002	157
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial Renato D. Lópes, Celestia S. Higano, Susan F. Slovin, Circulation	2021	141
Decreased Plasma Lipoprotein Lipase in Hypoadiponectinemia Maximilian von Eynatten, Jochen G. Schneider, Per M. Humpert, Diabetes Care	2004	138

Page 1